by Vandana Singh | Jan 26, 2026 | General
On Monday, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to Cogent Biosciences, Inc.’s (NASDAQ:COGT) bezuclastinib in combination with sunitinib for patients with Gastrointestinal Stromal Tumors (GIST). The trial included...
by Benzinga Insights | Jan 26, 2026 | General
In today’s rapidly changing and fiercely competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze companies. In this article, we will conduct a comprehensive industry comparison, evaluating Netflix...
by Benzinga Insights | Jan 26, 2026 | General
Amidst the fast-paced and highly competitive business environment of today, conducting comprehensive company analysis is essential for investors and industry enthusiasts. In this article, we will delve into an extensive industry comparison, evaluating Micron...
by Benzinga Insights | Jan 26, 2026 | General
Cleveland-Cliffs (NYSE:CLF) has outperformed the market over the past 10 years by 11.53% on an annualized basis producing an average annual return of 25.33%. Currently, Cleveland-Cliffs has a market capitalization of $8.66 billion. Buying $1000 In CLF: If an investor...
by Benzinga Insights | Jan 26, 2026 | General
Looking into the current session, Eli Lilly and Co Inc. (NYSE:LLY) shares are trading at $1060.01, after a 0.40% drop. Over the past month, the stock decreased by 1.76%, but over the past year, it actually went up by 31.78%. With questionable short-term performance...
Recent Comments